Crouse, Jacob J. http://orcid.org/0000-0002-3805-2936
Chitty, Kate M.
Iorfino, Frank
Carpenter, Joanne S.
White, Django
Nichles, Alissa
Zmicerevska, Natalia
Guastella, Adam J.
Scott, Elizabeth M.
Lee, Rico S. C.
Naismith, Sharon L.
Scott, Jan
Hermens, Daniel F.
Hickie, Ian B.
Funding for this research was provided by:
Australian Government
Department of Health | National Health and Medical Research Council (1061043, 511921)
Article History
Received: 3 July 2019
Revised: 30 December 2019
Accepted: 10 January 2020
First Online: 21 January 2020
Conflict of interest
: The current study was supported by the following: an Australian Government Research Training Program Scholarship (awarded to J.J.C.), National Health & Medical Research Council Center of Research Excellence Grant (No. 1061043) and an Australia Fellowship (No. 511921) (awarded to I.B.H.). Mr. Jacob J. Crouse has nothing to disclose. Dr. Kate M. Chitty has nothing to disclose. Dr. Frank Iorfino has nothing to disclose. Dr. Joanne S. Carpenter has nothing to disclose. Mr. Django White has nothing to disclose. Ms. Alissa Nichles has nothing to disclose. Ms. Natalia Zmicerevska has nothing to disclose. Prof. Adam J. Guastella has nothing to disclose. Associate Prof. Elizabeth M. Scott reports personal fees from St. Vincent’s Private Hospital, grants from Servier, personal fees from Servier, personal fees from Eli-Lilly, personal fees from Pfizer, outside the submitted work. A/Prof. Elizabeth Scott is the Medical Director, Young Adult Mental Health Unit, St. Vincent’s Hospital Darlinghurst, Discipline Leader of Adult Mental Health, School of Medicine, University of Notre Dame, Research Affiliate, The University of Sydney and Consultant Psychiatrist. She has received honoraria for educational seminars related to the clinical management of depressive disorders supported by Servier and Eli-Lilly pharmaceuticals. She has participated in a national advisory board for the antidepressant compound Pristiq, manufactured by Pfizer. She was the National Coordinator of an antidepressant trial sponsored by Servier. Dr. Rico S. C. Lee has nothing to disclose. Prof. Sharon L. Naismith has nothing to disclose. Prof. Jan Scott has nothing to disclose. Prof. Daniel F. Hermens has nothing to disclose. Prof. Ian B. Hickie reports personal fees from National Mental Health Commission, personal fees from Medibank Clinical Reference Group, non-financial support from Psychosis Australia Trust, grants from NHMRC, grants from Innowell Pty LTD, grants from NHMRC, grants from NHMRC, outside the submitted work. Professor Ian Hickie was an inaugural Commissioner on Australia’s National Mental Health Commission (2012–2018). He is the Co-Director, Health and Policy at the Brain and Mind Center (BMC) University of Sydney. The BMC operates an early-intervention youth services at Camperdown under contract to headspace. Professor Hickie has previously led community-based and pharmaceutical industry-supported (Wyeth, Eli Lily, Servier, Pfizer, AstraZeneca) projects focused on the identification and better management of anxiety and depression. He was a member of the Medical Advisory Panel for Medibank Private until October 2017, a Board Member of Psychosis Australia Trust and a member of Veterans Mental Health Clinical Reference group. He is the Chief Scientific Advisor to, and an equity shareholder in, Innowell. Innowell has been formed by the University of Sydney and PwC to deliver the $30 m Australian Government-funded “Project Synergy”. Project Synergy is a three-year program for the transformation of mental health services through the use of innovative technologies.